InfuSystems Holdings (FRA:1TZ) ROCE % : -3.86% (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is InfuSystems Holdings ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. InfuSystems Holdings's annualized ROCE % for the quarter that ended in Mar. 2024 was -3.86%.

InfuSystems Holdings ROCE % Historical Data

The historical data trend for InfuSystems Holdings's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

InfuSystems Holdings ROCE % Chart

InfuSystems Holdings Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

6.50

12.86

3.43

1.86

4.61

InfuSystems Holdings Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
ROCE %	Get a 7-Day Free Trial															-0.65	5.58	7.64	5.56	-3.86

InfuSystems Holdings ROCE % Calculation

InfuSystems Holdings's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	3.687	/	( ( (93.822 - 13.657)	+	(94.373 - 14.409) )	/ 2 )
	=	3.687	/	( (80.165	+	79.964)	/ 2 )
	=	3.687	/	80.0645
	=	4.61 %

InfuSystems Holdings's ROCE % of for the quarter that ended in Mar. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	-3.1	/	( ( (94.373 - 14.409)	+	(96.462 - 15.927) )	/ 2 )
	=	-3.1	/	( ( 79.964	+	80.535 )	/ 2 )
	=	-3.1	/	80.2495
	=	-3.86 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

InfuSystems Holdings (FRA:1TZ) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

InfuSystems Holdings ROCE % Related Terms

Thank you for viewing the detailed overview of InfuSystems Holdings's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

InfuSystems Holdings (FRA:1TZ) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » InfuSystems Holdings Inc (FRA:1TZ) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

INFU:USA

Address

3851 West Hamlin Road, Rochester Hills, MI, USA, 48309

Website

http://www.infusystem.com

InfuSystems Holdings Inc is a United States based healthcare service provider. It offers Infusion pumps and related products and services for patients in the home, oncology clinics, ambulatory surgery centers, and other sites of care from the locations in the United States and Canada. The company provides products and services to hospitals, oncology practices and chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states. The segments of the company are Integrated Therapy Services (ITS) and Durable Medical Equipment (DME) services, of which key revenue is derived from the ITS segment.

InfuSystems Holdings (FRA:1TZ) Headlines

No Headlines